Huons signed a domestic distribution and joint promotion agreement with Sanofi for five vaccine products on Wednesday at its headquarters in Pangyo.

Under this contract, starting April 1, Huons will oversee the domestic distribution and promotion of five vaccines: the influenza vaccines Vaxigrip and Efluelda, the adult diphtheria, tetanus, and pertussis vaccine Adacel, the hepatitis A vaccine Avaxim 160, and the meningococcal vaccine MenQuadfi.

Sanofi, a global biopharmaceutical leader, drives innovation through research and development (R&D) and artificial intelligence (AI), providing life-saving medicines and vaccines to millions worldwide.

Huons brings to the table its expertise in injectable drug sales and cold chain logistics within South Korea. The partnership is expected to create synergies in targeting the domestic vaccine market.

Huons recently established a dedicated Vaccine Business Division to strategically advance its vaccine initiatives. The company plans to leverage its experienced sales force and extensive customer network to improve access to world-class vaccines for healthcare providers and patients across South Korea.

Drawing on its experience with refrigerated injectables like Meritz C and Hudaxin, Huons aims to ensure reliable nationwide delivery of temperature-sensitive vaccines to medical facilities, utilizing its advanced cold chain management technology and logistics infrastructure.

Huons Chief Executive Officer (CEO) Song Soo-young remarked that its collaboration with Sanofi marks a pivotal moment in Huons' evolution into a global public health partner. By combining Sanofi's innovative solutions with the pharmaceutical sales expertise, it aims to set new benchmarks in the domestic vaccine market.

Huons signed a domestic distribution and joint promotion agreement with Sanofi for five va …

How Huons and Sanofi's Vaccine Partnership Will Transform the Korean Market in 2026